Literature DB >> 20388781

Downregulation of HtrA1 promotes resistance to anoikis and peritoneal dissemination of ovarian cancer cells.

Xiaoping He1, Takayo Ota, Peng Liu, Changqing Su, Jeremy Chien, Viji Shridhar.   

Abstract

We previously identified serine protease HtrA1 as a downregulated gene in epithelial ovarian cancer (EOC), but the functional consequence of loss of HtrA1 in EOC remains largely unclear. Here, we report that loss of HtrA1 attenuates anoikis--a critical physiologic barrier for tumor metastasis. In response to loss of anchorage, HtrA1 expression was upregulated in SKOV3 cells, resulting in autocatalytic activation of HtrA1. Stable knockdown of HtrA1 in SKOV3 and TOV21G cells resulted in resistance to anoikis due to enhanced activation of epidermal growth factor receptor (EGFR)/AKT pathway. In suspended SKOV3 cells, enhanced expression of HtrA1 inhibited EGFR/AKT pathway, leading to increased cell death, whereas protease-inactive mutant HtrA1 failed to result in either the inhibition of EGFR/AKT pathway or increased cell death, suggesting the requirement of HtrA1 protease activity in regulating anoikis. Immunoprecipitation and immunofluorescence assays revealed that HtrA1 interacted with EGFR not only on the cell membrane but also in the nucleus. Most importantly, downregulation of HtrA1 significantly enhanced the peritoneal dissemination of SKOV3ip1 cells in nonobese diabetic/severe combined immunodeficient mice, with increased phospho-EGFR level in corresponding tumor nodules compared with that in xenografts originated from the control cells. Taken together, these data reveal for the first time a novel function of HtrA1 in promoting anoikis by attenuating activation of EGFR/AKT pathway that may contribute to its metastasis suppression capacity, thus providing a possible explanation for the aggressive nature of human ovarian tumors with downregulated HtrA1. (c) 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20388781      PMCID: PMC5579484          DOI: 10.1158/0008-5472.CAN-09-3557

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Intestinal epithelial cancer cell anoikis resistance: EGFR-mediated sustained activation of Src overrides Fak-dependent signaling to MEK/Erk and/or PI3-K/Akt-1.

Authors:  Marie-Josée Demers; Sonya Thibodeau; Dominique Noël; Naoya Fujita; Takashi Tsuruo; Rémy Gauthier; Mélina Arguin; Pierre H Vachon
Journal:  J Cell Biochem       Date:  2009-07-01       Impact factor: 4.429

2.  Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer.

Authors:  Amanda Psyrri; Mohamad Kassar; Ziwei Yu; Aris Bamias; Paul M Weinberger; Sonia Markakis; Diane Kowalski; Robert L Camp; David L Rimm; Meletios A Dimopoulos
Journal:  Clin Cancer Res       Date:  2005-12-15       Impact factor: 12.531

3.  Induction of anoikis and suppression of human ovarian tumor growth in vivo by down-regulation of Bcl-X(L).

Authors:  A Frankel; K Rosen; J Filmus; R S Kerbel
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

Review 4.  Anchorage dependence, integrins, and apoptosis.

Authors:  E Ruoslahti; J C Reed
Journal:  Cell       Date:  1994-05-20       Impact factor: 41.582

5.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.

Authors:  Sooryanarayana Varambally; Jianjun Yu; Bharathi Laxman; Daniel R Rhodes; Rohit Mehra; Scott A Tomlins; Rajal B Shah; Uma Chandran; Federico A Monzon; Michael J Becich; John T Wei; Kenneth J Pienta; Debashis Ghosh; Mark A Rubin; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

6.  Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity.

Authors:  Jeremy Chien; Giovanni Aletti; Alfonso Baldi; Vincenzo Catalano; Pietro Muretto; Gary L Keeney; Kimberly R Kalli; Julie Staub; Michael Ehrmann; William A Cliby; Yean Kit Lee; Keith C Bible; Lynn C Hartmann; Scott H Kaufmann; Viji Shridhar
Journal:  J Clin Invest       Date:  2006-06-08       Impact factor: 14.808

7.  Nuclear localization of EGF receptor and its potential new role as a transcription factor.

Authors:  S Y Lin; K Makino; W Xia; A Matin; Y Wen; K Y Kwong; L Bourguignon; M C Hung
Journal:  Nat Cell Biol       Date:  2001-09       Impact factor: 28.824

8.  Suppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancer.

Authors:  Xiaohui Yu; Ling Liu; Bin Cai; Yinyan He; Xiaoping Wan
Journal:  Cancer Sci       Date:  2008-01-14       Impact factor: 6.716

Review 9.  HtrA serine proteases as potential therapeutic targets in cancer.

Authors:  Jeremy Chien; Mara Campioni; Viji Shridhar; Alfonso Baldi
Journal:  Curr Cancer Drug Targets       Date:  2009-06       Impact factor: 3.428

10.  B1 integrin/Fak/Src signaling in intestinal epithelial crypt cell survival: integration of complex regulatory mechanisms.

Authors:  Véronique Bouchard; Charlène Harnois; Marie-Josée Demers; Sonya Thibodeau; Vincent Laquerre; Rémy Gauthier; Anne Vézina; Dominique Noël; Naoya Fujita; Takashi Tsuruo; Mélina Arguin; Pierre H Vachon
Journal:  Apoptosis       Date:  2008-04       Impact factor: 4.677

View more
  29 in total

1.  AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer.

Authors:  Melissa K Brunckhorst; Dimitry Lerner; Shaomeng Wang; Qin Yu
Journal:  Cancer Biol Ther       Date:  2012-06-06       Impact factor: 4.742

2.  Diindolylmethane-mediated Gli1 protein suppression induces anoikis in ovarian cancer cells in vitro and blocks tumor formation ability in vivo.

Authors:  Prabodh K Kandala; Sanjay K Srivastava
Journal:  J Biol Chem       Date:  2012-07-06       Impact factor: 5.157

3.  Protective effects of an HTRA1 insertion-deletion variant against age-related macular degeneration in the Chinese populations.

Authors:  Tsz Kin Ng; Xiao Ying Liang; Fang Lu; David Tl Liu; Gary Hf Yam; Li Ma; Pancy Os Tam; Haoyu Chen; Ling Ping Cen; Li Jia Chen; Zhenglin Yang; Chi Pui Pang
Journal:  Lab Invest       Date:  2016-11-14       Impact factor: 5.662

4.  Role of CD24 in anoikis resistance of ovarian cancer cells.

Authors:  Yan-Hui Li; Xiang Sun; Hong-Bo Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-06-14

5.  Anoikis evasion in inflammatory breast cancer cells is mediated by Bim-EL sequestration.

Authors:  C L Buchheit; B L Angarola; A Steiner; K J Weigel; Z T Schafer
Journal:  Cell Death Differ       Date:  2014-12-19       Impact factor: 15.828

6.  HtrA1 sensitizes ovarian cancer cells to cisplatin-induced cytotoxicity by targeting XIAP for degradation.

Authors:  Xiaoping He; Ashwani Khurana; Jacie L Maguire; Jeremy Chien; Viji Shridhar
Journal:  Int J Cancer       Date:  2011-04-25       Impact factor: 7.396

7.  Serine protease HtrA1 as an inhibitor on proliferation invasion and migration of gastric cancer.

Authors:  Zhiguo Zhao; Huifang Li; Chuanyi Wang; Wanfang Xu; Junfeng Sun; Wenzhao Zhao
Journal:  Med Oncol       Date:  2015-03-12       Impact factor: 3.064

8.  Notch3 overexpression promotes anoikis resistance in epithelial ovarian cancer via upregulation of COL4A2.

Authors:  Caitlin W Brown; Alexander S Brodsky; Richard N Freiman
Journal:  Mol Cancer Res       Date:  2014-08-28       Impact factor: 5.852

9.  HtrA1 upregulates the expression of ADAMTS-5 in HNPCs via the ERK/NF-κB/JNK signaling pathway.

Authors:  Dapeng Li; Yumin Wu; Yan Wu; Chenlie Ni; Pan Jiang; Jian Li; Lianghao Mao; Qiping Zheng; Jiawei Yue
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

10.  Loss of HSulf-1 expression enhances tumorigenicity by inhibiting Bim expression in ovarian cancer.

Authors:  Xiaoping He; Ashwani Khurana; Debarshi Roy; Scott Kaufmann; Viji Shridhar
Journal:  Int J Cancer       Date:  2014-03-28       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.